PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2016 | 6 | 3 | A128-133
Article title

Maintenance chemotherapy with pemetrexed in patients with malignant pleural mesothelioma – case series and review of the literature

Content
Title variants
Languages of publication
EN
Abstracts
EN
Malignant pleural mesothelioma is a rare neoplasm with poor prognosis. Surgical complete resection, which is the only radical therapy available, is only possible in a minority of patients who suffer from a locally advanced disease. Radiotherapy can be considered as an adjuvant therapy after surgery or as supportive treatment in palliative care. Attempts are also made at combining it with chemotherapy. In cases of locally advanced, non-resectable or metastatic disease, chemotherapy remains the treatment of choice. The most effective palliative chemotherapy is the pemetrexed plus cisplatin regimen. We describe 3 cases of patients who underwent standard palliative chemotherapy with pemetrexed and cisplatin, manifesting good radiological and clinical response, followed by maintenance therapy with pemetrexed. The use of pemetrexed maintenance therapy helped achieve many years of disease control with acceptable toxicity. The consecutive stages of therapy were continuously discussed with our patients, and their informed consent was obtained. Pemetrexed maintenance therapy is not a standard procedure, but recent findings suggest it may be an efficacious option to consider in selected groups of patients. Further randomized prospective studies are needed, but a limiting factor is the rarity of the disease.
Discipline
Publisher

Journal
Year
Volume
6
Issue
3
Pages
A128-133
Physical description
Contributors
author
  • Department of Oncology, Military Institute of Medicine in Warsaw, Poland
  • Department of Oncology, Military Institute of Medicine in Warsaw, Poland
References
  • 1. Krajowy Rejestr Nowotworów [National Cancer Registry] [online: http://onkologia.org.pl/miedzybloniak-oplucnej-c45/].
  • 2. Liu F, Zhao B, Krug LM et al. Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer- aided volumetric measurement on computed tomography scans. J Thorac Oncol 2010; 5(6): 879-884.
  • 3. Common Terminology Criteria for adverse events (Version 4.0) [online: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_Quick- Reference_5x7.pdf].
  • 4. Krzakowski M, Orłowski T. Międzybłoniak opłucnej [Pleural Mesothelioma]. In: Jassem J, Krzakowski M (ed). Nowotwory klatki piersiowej [Thoracic Neoplasms]. Via Medica, Gdańsk 2013: 161-163.
  • 5. Lang-Lazdunski L. Surgery for malignant pleural mesothelioma: why, when and what? Lung Cancer 2014; 84(2): 103-109.
  • 6. Ellis P, Davies AM, Evans WK et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006; 1(6): 591-601.
  • 7. Berghmans T, Paesmans M, Lalami Y et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002; 38(2): 111-121.
  • 8. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21(14): 2636-2644.
  • 9. Santoro A, O’Brien ME, Stahel RA et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma. J Thorac Oncol 2008; 3: 756-763.
  • 10. Srour S, Stoner J. Pemetrexed in combination with cisplatin versus carboplatin as first-line therapy in patients with advanced-stage malignant pleural mesothelioma (MPM): A systematic review and meta-analysis. J Clin Oncol 2016; 34(suppl; abstr 8554). 2016 ASCO Annual Meeting.
  • 11. Zalcman G, Mazieres J, Margery J et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387(10026): 1405-1414.
  • 12. Jassem J, Ramlau R, Santoro A et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008; 26(10): 1698-1704.
  • 13. Ceresoli GL, Zucali PA, De Vincenzo F et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011; 72(1): 73-77.
  • 14. NCCN Guidelines Version 3.2016 [online: https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf].
  • 15. Stebbing J, Powles T, McPherson K et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009; 63: 94-97.
  • 16. Zucali PA, Perrino M, Lorenzi E et al. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer 2014; 84(3): 265-270.
  • 17. Zauderer MG, Kass SL, Woo K et al. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer 2014; 84: 271-274.
  • 18. Kelly RJ, Sharo E, Hassan R. Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer 2011; 73(3): 256-263.
  • 19. Hassan R, Jennens R, Van Meerbeeck J et al. A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140). J Clin Oncol 2016; 34(suppl; abstr TPS8576). 2016 ASCO Annual Meeting.
  • 20. Hassan R, Thomas A, Patel M et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression. J Clin Oncol 2016; 34(suppl; abstr 8503). 2016 ASCO Annual Meeting.
  • 21. Hassan R, Alley E, Kindler H, et al. CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM). J Clin Oncol 2016; 34 (suppl; abstr 8558). 2016 ASCO Annual Meeting.
  • 22. Kindler H, Scherpereel A, Calabrò L et al. Tremelimumab as second-or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study. J Clin Oncol 2016; 34(suppl; abstr 8502). 2016 ASCO Annual Meeting.
  • 23. Purohit A, Moreau L, Dietemann A et al. Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma. Lung Cancer 1998; 22: 119-125.
  • 24. Planting AS, van der Burg ME, Goey SH et al. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann Oncol 1995; 6: 613-615.
  • 25. Takeda T, Itano H, Fukita S et al. Long progression-free survival by pemetrexed continuation maintenance therapy following cisplatin-based chemotherapy in malignant pleural mesothelioma. Intern Med 2014; 53(20): 2347-2351.
  • 26. van den Bogaert DP, Pouw EM, van Wijhe G et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 2006; 1: 25-30.
  • 27. Pemetrexed Disodium or Observation in Treating Patients with Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy [online: https://clinicaltrials.gov/ct2/show/NCT01085630].
  • 28. Buikhuisen WA, Burgers JA, Vincent AD et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol 2013; 14(6): 543-551.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-89d6c39d-7c5a-442e-940f-b74a4d7f306e
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.